Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Alliance Foundation Trials, LLC.
Dana-Farber Cancer Institute
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Gilead Sciences
Cellectar Biosciences, Inc.
The Lymphoma Academic Research Organisation
City of Hope Medical Center
Merck Sharp & Dohme LLC
Peking University Third Hospital
University of Washington
Fondazione Italiana Linfomi - ETS
The Lymphoma Academic Research Organisation
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The Lymphoma Academic Research Organisation
Acerta Pharma BV
Emory University
Eli Lilly and Company
BeOne Medicines
Sun Yat-sen University
Guangzhou Lupeng Pharmaceutical Company LTD.
The Lymphoma Academic Research Organisation
Masonic Cancer Center, University of Minnesota
Fondazione Italiana Linfomi - ETS
City of Hope Medical Center
M.D. Anderson Cancer Center
Mayo Clinic
Gilead Sciences
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
H. Lee Moffitt Cancer Center and Research Institute
Ruijin Hospital
Fondazione Italiana Linfomi - ETS
University of Utah
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
M.D. Anderson Cancer Center